Technical Analysis for TSHA - Taysha Gene Therapies, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 2.17 | 7.71% | 0.16 |
TSHA closed down 5.19 percent on Wednesday, November 20, 2024, on 2.28 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to find support at its 50 day moving average.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Support | Bullish | 7.71% | |
| Calm After Storm | Range Contraction | 7.71% | |
| NR7 | Range Contraction | 7.71% | |
| Wide Bands | Range Expansion | 7.71% | |
| Calm After Storm | Range Contraction | 2.12% | |
| Wide Bands | Range Expansion | 2.12% | |
| Gapped Down | Weakness | 2.12% | |
| Wide Bands | Range Expansion | -5.04% | |
| 50 DMA Support | Bullish | 5.10% | |
| Wide Bands | Range Expansion | 5.10% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 1 hour ago |
| Up 5% | about 1 hour ago |
| 10 DMA Support | about 1 hour ago |
| 60 Minute Opening Range Breakout | about 1 hour ago |
| Up 3% | about 1 hour ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/12/2024
Taysha Gene Therapies, Inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; TSHA-102 for the treatment of Rett syndrome; TSHA-103 for the treatment of SLC6A1 haploinsufficiency disorder; and TSHA-104 for the treatment for Surfeit locus 1 deficiency. The company also has strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. Taysha Gene Therapies, Inc. was founded in 2019 and is based in Dallas, Texas.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Rare Diseases Gene Therapy Lipid Storage Disorders Monogenic Deficiency Monogenic Diseases Gangliosidosis Gm2 Gangliosidoses Gm2 Gangliosidosis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Rare Diseases Gene Therapy Lipid Storage Disorders Monogenic Deficiency Monogenic Diseases Gangliosidosis Gm2 Gangliosidoses Gm2 Gangliosidosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.32 |
| 52 Week Low | 1.19 |
| Average Volume | 3,783,885 |
| 200-Day Moving Average | 2.41 |
| 50-Day Moving Average | 1.97 |
| 20-Day Moving Average | 1.84 |
| 10-Day Moving Average | 1.99 |
| Average True Range | 0.23 |
| RSI (14) | 52.15 |
| ADX | 27.92 |
| +DI | 24.97 |
| -DI | 19.94 |
| Chandelier Exit (Long, 3 ATRs) | 1.94 |
| Chandelier Exit (Short, 3 ATRs) | 1.88 |
| Upper Bollinger Bands | 2.51 |
| Lower Bollinger Band | 1.16 |
| Percent B (%b) | 0.63 |
| BandWidth | 73.51 |
| MACD Line | 0.05 |
| MACD Signal Line | -0.01 |
| MACD Histogram | 0.0611 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.25 | ||||
| Resistance 3 (R3) | 2.26 | 2.19 | 2.21 | ||
| Resistance 2 (R2) | 2.19 | 2.13 | 2.19 | 2.20 | |
| Resistance 1 (R1) | 2.10 | 2.09 | 2.07 | 2.09 | 2.18 |
| Pivot Point | 2.03 | 2.03 | 2.01 | 2.03 | 2.03 |
| Support 1 (S1) | 1.94 | 1.97 | 1.91 | 1.93 | 1.84 |
| Support 2 (S2) | 1.87 | 1.93 | 1.87 | 1.82 | |
| Support 3 (S3) | 1.78 | 1.87 | 1.81 | ||
| Support 4 (S4) | 1.77 |
